ArticleJournal of advanced research2023
Naringenin in Si-Ni-San formula inhibits chronic psychological stress-induced breast cancer growth and metastasis by modulating estrogen metabolism through FXR/EST pathway.
Article in Journal of advanced research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Effects of Naringenin in Preclinical Models of Breast Cancer.Biomolecules · 2026Review
- Psychological crisis in patients with primary liver cancer after transarterial chemoembolization: epidemiological characteristics and associated factors.World journal of surgical oncology · 2026Article
- Unveiling the relationship between stress-hyperglycemia ratio and cardiometabolic multimorbidity risk using interpretable machine learning.European journal of medical research · 2026Article
- Clinical efficacy and multi-omics analysis of Si-Ni-San for depression treatment in breast cancer patients: a randomized, double-blind, placebo-controlled, crossover trial.Chinese medicine · 2026Article
- Single status shows age dependent bidirectional effects in differentiated thyroid cancer.Scientific reports · 2025Article
- Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications.Cancer pathogenesis and therapy · 2025Review
- Diminished Estrogen Induced Mitochondrial Protection and Immunosuppressive Microenvironment in Gastric Cancer with Depression.Cancers · 2025Article
- Naringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies.Antioxidants (Basel, Switzerland) · 2025Review
- Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions.Signal transduction and targeted therapy · 2025Review
- Molecular mechanisms of the Xiao-chai-hu-tang on chronic stress-induced colorectal cancer growth based on an integrated network pharmacology and RNA sequencing approach with experimental validation.BMC complementary medicine and therapies · 2025Article
- Role, mechanisms and effects ofOncology letters · 2025Review
- Naringenin induces ferroptosis in osteosarcoma cells through the STAT3-MGST2 signaling pathway.Journal of bone oncology · 2025Article
- Dehydrodiisoeugenol targets the PLK1-p53 axis to inhibit breast cancer cell cycle.Frontiers in pharmacology · 2025Article
- Mechanism of total saponins ofFrontiers in pharmacology · 2025Article
- Chaihu Longgu Muli Decoction inhibits chronic stress-induced lung cancer epithelial-mesenchymal transition process by suppressing Rap1/ERK signal pathway.Frontiers in pharmacology · 2025Article
- Chronic Psychological Stress Activates TRP/TAM/CXCL1 Signaling to Promote Breast Cancer Adipocyte Lipolysis via KEAP1 mResearch (Washington, D.C.) · 2025Article
- The dual role of the gut microbiota in breast cancer: from pathogenic mechanisms to emerging therapeutic.Frontiers in microbiology · 2025Review
- Body Roundness Index Trajectories and the Risk of Cancer: A Cohort Study.Cancer medicine · 2024Article
- Application of omics technologies in studies on antitumor effects of Traditional Chinese Medicine.Chinese medicine · 2024Review
- Network pharmacology to explore the mechanism of traditional Chinese medicine in the treatment of ground glass nodules.Journal of thoracic disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic psychological stress is a well-established risk factor for breast cancer development. Si-Ni-San (SNS) is a classical traditional Chinese medicine formula prescribed to psychological disorder patients. However, its action effects, molecular mechanisms, and bioactive phytochemicals against breast cancer are not yet clear.
objectivesThis study aimed to explore the modulatory mechanism and bioactive compound of SNS in regulating estrogen metabolism during breast cancer development induced by chronic psychological stress.
methodsMouse breast cancer xenograft was used to determine the effect of SNS on breast cancer growth and metastasis. Metabolomics analysis was conducted to discover the impact of SNS on metabolic profile changes in vivo. Multiple molecular biology experiments and breast cancer xenografts were applied to verify the anti-metastatic potentials of the screened bioactive compound.
resultsSNS remarkably inhibited chronic psychological stress-induced breast cancer growth and metastasis in the mouse breast cancer xenograft. Meanwhile, chronic psychological stress increased the level of cholic acid, accompanied by the elevation of estradiol. Mechanistic investigation demonstrated that cholic acid activated farnesoid X receptor (FXR) expression, which inhibited hepatocyte nuclear factor 4α (HNF4α)-mediated estrogen sulfotransferase (EST) transcription in hepatocytes, and finally resulting in estradiol elevation. Notably, SNS inhibited breast cancer growth by suppressing estradiol level via modulating FXR/EST signaling. Furthermore, luciferase-reporting gene assay screened naringenin as the most bioactive compound in SNS for triggering EST activity in hepatocytes. Interestingly, pharmacokinetic study revealed that naringenin had the highest absorption in the liver tissue. Following in vivo and in vitro studies demonstrated that naringenin inhibited stress-induced breast cancer growth and metastasis by promoting estradiol metabolism via FXR/EST signaling.
conclusionThis study not only highlights FXR/EST signaling as a crucial target in mediating stress-induced breast cancer development, but also provides naringenin as a potential candidate for breast cancer endocrine therapy via promoting estradiol metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.